Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 05, 2023 08:00 ET | Source: Vor Biopharma

Vor Bio to Participate in the Goldman Sachs Healthcare Conference

CAMBRIDGE, Mass., June 05, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, will present and host in-person 1x1 investor meetings at the Goldman...
May 11, 2023 16:05 ET | Source: Vor Biopharma

Vor Bio Reports First Quarter 2023 Financial Results and Provides Company Update

VBP101 clinical data update planned at European Hematology Association (EHA) 2023VCAR33ALLO IND submission on-track for 1H 2023 CAMBRIDGE, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq:...
April 18, 2023 08:00 ET | Source: Vor Biopharma

Vor Bio to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming...
March 23, 2023 16:01 ET | Source: Vor Biopharma

Vor Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update

Initial clinical data supports founding vision that engineered hematopoietic stem cells can enable treatment options after AML transplantAdditional trem-cel data expected by year-end 2023; VCAR33ALLO...
February 21, 2023 08:00 ET | Source: Vor Biopharma

Vor Bio to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming...
February 16, 2023 12:00 ET | Source: Vor Biopharma

First AML Patient Transplanted with Vor Bio’s Trem-cel Demonstrated Durable Engraftment through Multiple Mylotarg™ Cycles at Initial Dose Level

Trem-cel exhibited robust engraftment five months post-transplant through three cycles of MylotargMylotarg treatment enriched CD33-negative donor hematopoiesisSecond patient successfully received...
January 19, 2023 08:00 ET | Source: Vor Biopharma

Vor Bio to Present Clinical Data from First Patient Treated with Trem-cel at 2023 Tandem Meetings

CAMBRIDGE, Mass., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that clinical data from the first patient treated in...
January 12, 2023 08:00 ET | Source: Vor Biopharma

Vor Bio to Present at B. Riley Securities’ 3rd Annual Oncology Conference

CAMBRIDGE, Mass., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate virtually in B. Riley...
December 07, 2022 07:45 ET | Source: Vor Biopharma

Vor Bio Prices Underwritten Offering of Common Stock and Concurrent Private Placement for Aggregate Proceeds of $115.8 Million

CAMBRIDGE, Mass., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the pricing of an underwritten offering and a private...
December 07, 2022 07:30 ET | Source: Vor Biopharma

First AML Patient Successfully Transplanted with Vor Bio’s Investigational Trem-cel (VOR33) and Tolerated Mylotarg™

Trem-cel (formerly VOR33) successfully manufactured and engrafted normallyBlood counts successfully maintained following post-transplant treatment with MylotargConference call scheduled for today,...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right